|
Found 96 result(s) FROM 1963 pages containing the term 'adalimumab'.
Thursday Nov 12, 2009
TNF Inhibitors Do Not Raise Cancer Risk
No increased cancer risk was seen during the first 6 years of anti-TNF therapy for rheumatoid arthritis...
Tuesday Oct 20, 2009
Infliximab Plus MTX for JIA
Infliximab plus methotrexate (MTX) bests combinations of traditional disease modifying drugs and/or MTX alone for the treatment of polyarticular juvenile idiopathic arthritis...
Wednesday Sep 30, 2009
FDA Finally OKs Stelara for Psoriasis
The FDA has approved Centocor's Stelara (ustekinumab) for moderate to severe psoriasis...
Wednesday Aug 05, 2009
Black Box Added to TNF Inhibitors for Kids, Teens
The FDA has expanded TNF blocker “black box” warnings to include lymphoma and other cancers in children and teens, leukemia in all patients, and new-onset psoriasis...
Wednesday Jul 29, 2009
TNF Inhibitors Have Different TB Risks
The risk of developing tuberculosis is 7 to 17 fold higher among patients receiving anti-TNF monoclonal antibody therapy than for those receiving soluble TNF receptors. How can you protect your patients?...
Thursday Jul 23, 2009
Gene Therapy Cleared in RA Patient Death
The vector used in an RA gene therapy study did not cause the death of a patient who died during the trial...
Wednesday May 20, 2009
X-ray Stability Lags RA Remission by Months
Radiographic joint damage grinds to a halt only after at least 9 months of sustained disease remission...
Thursday May 07, 2009
Abbott Sues Centocor Over Simponi Rights
Court fights over TNF inhibitors expand with Simponi approval...
Tuesday Feb 17, 2009
Some TNF Inhibitors Raise Shingles Risk in RA. Time to Vaccinate?
Anti-TNF monoclonal antibody drugs (adalimumab, infliximab) significantly increase herpes zoster risk in RA patients, and vaccination should be considered. Etanercept was not associated with increased herpes zoster risk...
Wednesday Feb 04, 2009
Anakinra Shows Modest Benefit, Some Risk in RA: Cochrane Review
The IL-1 receptor antagonist Anakinra (Kineret, Amgen) significantly improves rheumatoid arthritis (RA) patients but may be less effective than other biologicals...
Monday Sep 29, 2008
Abbott Reports Continuous Treatment With Humira® Achieves Superior Long-Term Efficacy for Psoriasis Patients in the US and Europe Versus Interrupting Treatment
The findings were from the company's pivotal 52-week REVEAL study and the period of open-label treatment that followed...
Monday Sep 08, 2008
FDA Warns of Histoplasmosis, Invasive Fungal Infections in Patients Taking TNF Inhibitors
The US Food and Drug Administration has issued a “MedWatch” warning about the risk of histoplasmosis and other invasive fungal infections in patients taking TNF blockers...
Wednesday Aug 27, 2008
Pivotal Humira Trial Shows Durable Benefit in Juvenile Rheumatoid Arthritis
The pivotal trial of adalimumab (Humira®) shows durable, safe efficacy for up to 2 years for children with polyarticular JRA and positions the TNF-inhibitor as the reasonable second-line drug to add if methotrexate does not provide sufficient disease control...
Monday Jul 28, 2008
NHS TNF Inhibitor Restrictions Heighten Impact of Baseline DAS28 in RA
The British National Institute for Health and Clinical Excellence (NICE) guidelines for approving access to TNF inhibitors for patients with rheumatoid arthritis (RA) may be unnecessarily extending the period when steroids are not allowed and classifying >30% of patients as “nonresponders” who would not be allowed to continue anti-TNF treatment...
Tuesday Jul 08, 2008
Rheumatologists Can Expect to See More HIV-Related Joint Problems as Mortality Drops
Mortality in HIV-infected patients has dropped comparable with general population levels, especially in those who begin highly active antiretroviral therapy (HAART) early, and one result is that rheumatologists can expect to see more long-term HIV survivors with joint problems related to the underlying HIV, treatment, or aging...
Thursday Jun 26, 2008
New ACR Guidelines Help Clinicians Incorporate Biologics Into RA Treatment Plans
The new American College of Rheumatology guidelines help rheumatologists to choose the right drugs and to monitor RA patients for untoward effects, but the guidelines should not replace sound clinical judgment…
Thursday Jun 12, 2008
Step-Up, Tight Control Abates Early RA in 50% of Patients by 36 Weeks
As many as half of all early rheumatoid arthritis patients may achieve remission within 36 weeks following step-up therapy coupled with tight control...
Monday Jun 09, 2008
FDA Launches Major Investigation of Cancer Risk in Children Taking TNF Blockers
The FDA is investigating a possible link between TNF blockers and cancer in children and young adults...
Friday May 09, 2008
Treating Early RA With Intensive Step-Up Triple-DMARDs is as Good Starting 3 At Once—Perhaps as Effective as Biologics
Intensive triple therapy with conventional DMARDs in early active RA is as effective as a step-up regimen and is as effective as when all 3 drugs are started together, and both approaches can achieve response rates as high as those seen with biologics…
Tuesday Apr 29, 2008
Recent Advances in the Management of Crohn's Disease
Biological agents offer advances in the treatment of Crohn’s disease, while surgery and autologous stem cell transplantation may be viable options for patients with severe refractory Crohn’s…
Thursday Apr 24, 2008
UCB’s Cimzia® Approved in the US for the Treatment of Moderate-to-Severe Crohn's Disease; Dosed Subcutaneously Every 4 Weeks
The US FDA has approved Cimzia® (certolizumab pegol), indicated for reducing signs and symptoms of Crohn’s disease and maintaining clinical response in adult patients with moderate-to-severe active disease who have an inadequate response to conventional therapy...
Monday Apr 21, 2008
Abbott’s Humira® (adalimumab) Approved in Japan for the Treatment of RA
Abbott received approval in Japan for Humira® (adalimumab) to treat RA in patients with inadequate response to conventional therapy...
Tuesday Apr 15, 2008
Granuloma Annulare Induced by Antitumor Necrosis Factor Therapy
Researchers found evidence of a link between TNF inhibition and the development of granuloma annulare skin lesions in some patients…
Monday Apr 07, 2008
Analysis Finds Etanercept, Adalimumab More Cost-Effective Than Infliximab for Medicare Use
A model comparing costs and effectiveness of the biologics currently covered for treating RA in US Medicare beneficiaries has shown that etanercept (ETN) and adalimumab (ADA) are both more cost-effective than infliximab (INF)…
Tuesday Feb 26, 2008
Abbott Receives FDA Approval for Humira® (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis; EOW Dosing
Abbott Laboratories announced it has received US FDA approval to market Humira® (adalimumab) as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis...
Thursday Feb 21, 2008
Stress Triggers TNFα Production in RA Patients—Unless They Are Taking a TNF Inhibitor
Psychological stress triggers monocyte TNFα production in RA patients, and TNFα inhibitors protect against this stress response, which may cause the disease flares often reported by patients after stressful experiences...
Friday Feb 08, 2008
TNF Inhibitors, Efalizumab, Alefacept Herald New Era in Psoriasis Treatment
New treatment strategies that include TNF-α inhibitors, efalizumab, and alefacept offer better psoriasis control with less toxicity, but still need to be compared with traditional agents in clinical trials...
Thursday Jan 24, 2008
TNFα Inhibitors Can Be Used Again After Treatment of TB Flare
TNFα inhibitors can be safely readministered after either a flare of latent TB or a new TB infection and should be considered an option in patients with otherwise uncontrollable RA...
Wednesday Jan 23, 2008
Abbott's Humira® Approved in US for Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
Abbott Laboratories announced it has received US FDA approval to market Humira® (adalimumab) for adults with moderate-to-severe chronic plaque psoriasis...
Tuesday Jan 15, 2008
Three More Cases of Significant Neutropenia Lead to Recommendation for Routine CBC Monitoring
Three more cases of significant neutropenia in rheumatoid arthritis (RA) and psoriatic arthritis patients treated with etanercept lead to a recommendation for regular monitoring of complete blood counts (CBC)...
Monday Jan 07, 2008
Abbott's Humira® Approved in the EU for Treatment of Moderate-to-Severe Plaque Psoriasis
Abbott announced it has received marketing authorization from the European Commission for the use of the TNF antagonist Humira® (adalimumab) as a treatment for moderate-to-severe plaque psoriasis. Humira is the first fully human, self-injectable biologic for the treatment of psoriasis...
Monday Dec 03, 2007
Targeted Genetics Announces That US FDA Removed Hold on Phase I/II Clinical Trial of tgAAC94 for Inflammatory Arthritis; Phase II Clinical Trial Protocol Design Underway
Targeted Genetics Corp announced that the US FDA removed the hold on the company's phase I/II clinical trial of tgACC94 for inflammatory arthritis, following the agency's review of the safety data thus far on all 127 subjects and all data from a fatal serious adverse event, which led to the death of a patient...
Monday Nov 26, 2007
Abatacept Wins Plaudits in Refractory JIA
The costimulation blocker abatacept may be a safe and effective option for juvenile idiopathic arthritis patients who have exhausted all other therapies...
Wednesday Nov 21, 2007
Combining MTX or Other DMARD With Biologic Seen as Best Strategy for MTX-Resistant Rheumatoid Arthritis
A systematic review of head-to-head trials and prospective cohort studies found little difference among either conventional DMARDs or anti-tumor necrosis factor (anti-TNF) drugs used as monotherapy, but suggests that adding a conventional DMARD to a biologic may be the best strategy for MTX-resistant RA...
Tuesday Nov 20, 2007
Abbott's Humira® Receives Positive Opinion From EMEA for Treatment of Moderate-to-Severe Plaque Psoriasis
Abbott Laboratories announced that the Committee for Medicinal Products for Human Use (CHMP), granted Abbott a positive opinion recommending approval of Humira® (adalimumab) for the treatment of moderate-to-severe plaque psoriasis...
Thursday Nov 15, 2007
Response to RA Therapy in First 3 Months Predicts Chance of Remission at 1 Year
Rheumatoid arthritis disease activity during the first 3 months of treatment predicts response at 1 year, and even partial response may "reset the baseline" for subsequent treatment...
Tuesday Nov 13, 2007
Targeted Genetics Reports Positive Interim Phase I/II Results for tgAAC94 in Inflammatory Arthritis; Tests Indicate tgAAC94 Did Not Contribute to Immunosuppression Leading to Fatal SAE
Targeted Genetics Corp, a clinical-stage biotechnology company, announced that interim data from its phase I/II trial of tgAAC94 for inflammatory arthritis suggest that the investigational therapy showed improvement in patient-reported outcome measures...
Friday Aug 31, 2007
TNF Inhibitors Raise Risk for Skin Cancers But Not Other Malignancies
The final report from a large observational study of more than 13,000 patients clears TNF inhibitors of increasing the incidence of solid tumors or lymphomas but finds that TNF-inhibitor treatment is associated with a significant increase in melanomas and other skin cancers…Wolfe F, et al. Arthritis Rheum. 2007;56:2886-2895.
Thursday Aug 23, 2007
NICE Issues Positive Appraisal of Abbott's Humira® (adalimumab) for the Treatment of Psoriatic Arthritis in UK Patient Population
The National Institute for Health and Clinical Excellence has published final guidance on the use of Humira® (adalimumab, Abbott Laboratories), a recombinant human monoclonal antibody that binds specifically to TNF-a, for the treatment of psoriatic arthritis (PsA)...
Friday Jun 15, 2007
Has the Increasing Use of Anti-TNF Drugs Led to a Rise in Cases of Drug-Induced Lupus? Study Says Yes
The increasing use of TNFα inhibitors to treat rheumatic, digestive, and cutaneous diseases has led to a corresponding rise in the number of cases of drug-induced lupus...
Monday Jun 11, 2007
Abbott's HUMIRA® (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
Abbott Laboratories announced that it has received marketing authorization from the European Commission for the use of Humira® (adalimumab) as a treatment for severe Crohn's disease (CD)...
Friday May 25, 2007
Accumulating Evidence Supports Adalimumab for Severe Psoriatic Arthritis
Adalimumab (Humira®) is safe and effective for patients with active psoriatic arthritis (PsA) who showed an inadequate response to disease-modifying antirheumatic drugs (DMARDs)...
Wednesday May 09, 2007
Abbott's ABT-874 Shows Positive Results in Phase II Psoriasis Study
Abbott Laboratories announced positive results from a 12-week, double-blind, placebo-controlled phase II study in which its investigational treatment, ABT-874, a fully human monoclonal antibody designed to target and neutralize interleukin-12 and interleukin-23, significantly reduced psoriasis symptoms in the majority of patients treated...
Monday Apr 16, 2007
Abbott Seeks US and EU Regulatory Approval for HUMIRA® (Adalimumab) in Psoriasis; Receives US FDA Approval in Crohn's Disease
Abbott Laboratories announced that it has simultaneously submitted a supplemental Biologics License Application (sBLA) with the US FDA and a Type II Variation to the European Medicines Agency (EMEA) seeking approval to market HUMIRA® (adalimumab) as a treatment for moderate-to-severe chronic plaque psoriasis, the fifth autoimmune disease targeted for HUMIRA therapy in both the US and Europe...
Thursday Apr 05, 2007
More Evidence Points Toward Safety of Anti-TNF Drugs During Pregnancy
Three recent case reports add to an accumulating body of evidence that the TNF-blockers are safe during pregnancy, but one new report is far from the final word on the issue...
Thursday Mar 22, 2007
6000-Patient Open-Label ReAct Study Shows Adalimumab Safe, Effective Alone or With DMARDs in Hard-to-Treat RA
The largest prospective study to date of the use of a TNF-inhibitor in RA shows that adalimumab (Humira®) is safe and effective alone or in combination with standard disease-modifying antirheumatic drugs (DMARDs)...
Thursday Mar 22, 2007
New Studies Urge Closer Monitoring for JIA-Related Uveitis, TNF-Inhibitors Effective For Difficult Cases
New studies report that uveitis occurs in up to 20% of JIA patients, that TNF-inhibitors may be effective in hard-to-treat cases, and that close monitoring for uveitis should continue even during arthritis remissions...
Wednesday Feb 28, 2007
Abbott's HumiraR (Adalimumab) Receives FDA Approval for Self-Administered Treatment of Moderate-to-Severe Crohn's Disease; Represents 4th FDA Approval in Immune-Mediated Diseases for Humira
Abbott announced it has received US FDA approval to market Humira® (adalimumab, a fully human anti-TNF-α monoclonal antibody) as a treatment for reducing the signs and symptoms and inducing and maintaining clinical remission of moderately-to-severely active Crohn's disease (CD) in adults who have had an inadequate response to conventional therapy...
Monday Dec 11, 2006
Steroids, Cytotoxics Cause More Heart Damage than Biologics in Treating RA
Biologic immunosuppressive agents used to treat rheumatoid arthritis (RA) carry cardiovascular risks similar to that of methotrexate (MTX), but oral glucocorticoids and other cytotoxic RA drugs are more damaging to the heart...
Monday Nov 27, 2006
Rituximab in RA
Rituximab prevents joint damage, can be given repeatedly, and does not block response to influenza vaccine in RA patients... Presented at ACR 2006 Meeting.
Thursday Nov 16, 2006
Abbott's HUMIRA (adalimumab) Approved in Canada for Treatment of Ankylosing Spondylitis
Abbott announced that it has received approval from Health Canada to market HumiraR (adalimumab) as a treatment for active ankylosing spondylitis (AS) in Canada.
Thursday Oct 19, 2006
Access to TNF-Blockers Severely Limited in UK
Access to TNF-inhibitor treatment is limited even for British RA patients who meet official guidelines for treatment, and is even more limited for patients with psoriatic arthritis or ankylosing spondylitis ... Kay, LJ, et al. Rheumatology. 2006 Oct 11; [Epub ahead of print].
Monday Sep 25, 2006
Rituximab Quickly Reduces Disease Activity in Treatment-Resistant RA
Rituximab added to methotrexate significantly reduces disease activity in patients whose RA is resistant to TNF inhibitors... Cohen SB, et al. Arthritis Rheum. 2006;54:2793-2806.
Tuesday Sep 19, 2006
TNF Inhibitors Do Not Increase Cancer Risk More Than MTX in RA Patients
A study of 1152 RA patients who used biologics and 7306 treated with methotrexate concludes that the risk of cancer is about the same in both groups, once RA disease severity is considered. Setoguchi S, et al. Arthritis Rheum. 2006;54:2757-2764.
Monday Sep 11, 2006
Abbott Seeks US and EU Approvals for HUMIRA (Adalimumab) for Crohn's Disease
Abbott announced it has simultaneously submitted a supplemental Biologics License Application with the US FDA and a Type II Variation to the European Medicines Agency seeking approval to market HUMIRAR (adalimumab) as a treatment for moderate-to-severe Crohn's disease...
Thursday Aug 03, 2006
British Registry Data Show Safety of First-Trimester TNF Inhibitor Exposure, Safety of Later Use Still Unclear
Data from a British registry of TNF inhibitor users suggest that brief exposure to TNF inhibitors during the first trimester of pregnancy is not harmful either to women who inadvertently become pregnant while taking these drugs or to their babies, but raise questions about safety in later pregnancy... Hyrich KL, et al. Arthritis Rheum. 2006;54:2701-2702.
Tuesday Aug 01, 2006
Schering-Plough's REMICADE Receives EU Approval as Monotherapy for Treatment of Psoriatic Arthritis; Abbott's HUMIRA Receives FDA Approval for Treatment of Ankylosing Spondylitis
Schering-Plough Corporation announced that the European Commission approved the use of REMICADE® (infliximab) as monotherapy in the treatment of active and progressive psoriatic arthritis (PsA) in patients who show intolerance to methotrexate (MTX) or for whom MTX is contraindicated.
Tuesday Jun 27, 2006
Abbott Receives FDA Approval for New HUMIRA® Injection Device
Abbott Laboratories announced that the US FDA approved the HUMIRA® Pen, a new single-use, disposable, pen-like device for administering HUMIRA, a treatment approved in the US for moderate-to-severe rheumatoid arthritis and for active psoriatic arthritis....
Thursday Jun 22, 2006
JRA Patients Do Better With Adalimumab, With or Without MTX
Phase III data show that adalimumab quickly and durably reduces disease flares and improves response rates in children with juvenile rheumatoid arthritis... Ruperto N; 2006 EULAR Meeting. Ann Rheum Dis. 2006;65(suppl):OP0007.
Monday Jun 12, 2006
Abbott's Humira® Approved in European Union for Severe Ankylosing Spondylitis
Abbott Laboratories announced that Humira® (adalimumab) was approved by the European Commission for marketing in Europe as a treatment for severe, active ankylosing spondylitis...
Tuesday May 16, 2006
TNF Inhibitors Raise Cancer, Infection Risk, but Are Still Best Bet for Many RA Patients
A new meta-analysis shows that RA patients treated with infliximab or adalimumab (in addition to methotrexate) had 3.3 times the risk of developing cancer and 2.2 times the risk of developing a serious infection compared to their counterparts taking placebo plus methotrexate, and patients should be advised to get vaccinations, be alert for symptoms of infection, and have regular cancer screenings... Bongartz T, et al. JAMA. 2006;295:2275-2285.
Monday May 08, 2006
Additional Neuropathies Linked to TNF Inhibitors
Guillain-Barré syndrome, demyelinating and axonal neuropathies, and a central nervous system syndrome have been reported recently in patients treated with TNF inhibitors... Shin I-SJ, et al. Arthritis Rheum. 2006;54:1429-1434; Jarand J, et al. J Rheumatol. 2006;33:1018-1020.
Monday May 01, 2006
Abbott's HumiraR (Adalimumab) Receives Positive Opinion From EMEA for Ankylosing Spondylitis
Abbott Laboratories, of Abbott Park, Illinois, announced that the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMEA), issued a positive opinion recommending approval of Humira® (adalimumab)...
Wednesday Apr 26, 2006
Infliximab Suspected of Worsening Rare MTX Lung Problem
Interstitial pneumonitis occurs in less than 1% of patients treated with methotrexate (MTX), but a recent case report suggests that adding infliximab might increase lung toxicity risk in certain vulnerable patients... Villeneuve E, et al. J Rheumatol. 2006 Apr 15; [Epub ahead of print]
Wednesday Apr 26, 2006
TNF-alpha Inhibitors Increase Postop Infection Risk in RA Patients
The first systematic investigation linking TNF inhibitor therapy in RA to postoperative infections suggests that clinicians should consider interrupting anti-TNF treatment prior to orthopaedic surgery procedures... Giles JT, et al. Arthritis Rheum. 2006;55:333-337
Thursday Feb 16, 2006
Infliximab Effective Treatment for Refractory Childhood Uveitis
Tumor necrosis factor-alpha inhibition is effective for treatment of childhood uveitis refractory to standard immunosuppressive therapy... Saurenmann RK, et al. Rheumatology Advance Access. February 3, 2006.doi:10.1093/rheumatology/ke1030.
Monday Jan 30, 2006
Sales of Abbott's Humira® Exceed $1B in 2005
Abbott Laboratories reported that worldwide sales for Humira® (adalimumab) reached $1.4 billion...
Wednesday Jan 25, 2006
Insurance Coverage May Influence How TNF-Alpha Inhibitors Are Prescribed
A new observational study of the TNF-α inhibitors infliximab and etanercept has found that Medicare patients with RA are 30% more likely to receive infliximab than those covered by private insurance, findings that suggest that reimbursement policies may drive physicians' prescribing decisions independent of efficacy. However, the emergence of Medicare Part D prescription coverage may change prescribing behavior to favor self-injectable drugs... DeWitt EM, et al. Arch Intern Med. 2006;166:57-63.
Tuesday Jan 10, 2006
ARMADA Trial Supports Long-Term Safety and Efficacy of Adalimumab and Background Methotrexate for RA
Adalimumab plus background methotrexate is a safe and well-tolerated combination that has demonstrated a sustained clinical response and remission in patients with active rheumatoid arthritis (RA) for up to 4 years... Weinblatt ME, et al. Ann Rheum Dis. Published online Dec. 16, 2005; doi:10.1136/ard.2005.044404.
Wednesday Jan 04, 2006
Eisai and Abbott Submit NDA in Japan for RA Drug Adalimumab
Eisai Co, Ltd, and Abbott Japan Co, Ltd, have announced the submission of a new drug application (NDA) to the Minister of Health, Labor and Welfare in Japan for the rheumatoid arthritis (RA) drug adalimumab...
Monday Nov 21, 2005
Genentech, Biogen IDEC's Rituxan® Benefits RA Patients Unresponsive to Methotrexate and Anti-TNF Therapies
Genentech, Inc, and Biogen IDEC, who filed in October for US Food and Drug Administration approval to market rituximab (Rituxan®)...
Wednesday Nov 16, 2005
TNF-α Antagonist Adalimumab Shows Promise in AS
Encouraging results from the ATLAS trial suggest that adalimumab and other TNF-α inhibitors may be effective in reducing the signs and symptoms of ankylosing spondylitis... Presented at: Annual Meeting of the American College of Rheumatology; November 12–17, 2005; San Diego, Calif.
Tuesday Nov 15, 2005
Despite Demonstrated Efficacy of Anti-TNF Therapies, Many Patients Stop Treatment
While biologic therapies targeted against tumor necrosis factor-alpha (TNF-α) have built a "satisfactory" track record in rheumatologic conditions, this emerging standard of care is still marked by a loss of efficacy over time and the withdrawal of patients from their initial therapy, indicating a need for improvement... Presented at: 69th Annual Meeting of the American College of Rheumatology; November 12–17, 2005; San Diego, Calif.
Monday Nov 07, 2005
Abbott's Humira® Demonstrates Maintenance of Clinical Remission in Phase III Extension
Results from a phase III extension study (CLASSIC II) presented at the 70th Annual Scientific Meeting and Postgraduate Course of the American College of Gastroenterology in Honolulu, Hawaii...
Tuesday Nov 01, 2005
CAT and Abbott Resolve Royalty Dispute Regarding Humira®
Cambridge Antibody Technology Group PLC (CAT), a British biotechnology company headquartered in Cambridge, England, and Illinois-based Abbott Laboratories have reached an agreement...
Thursday Oct 06, 2005
Abbott's HumiraR (Adalimumab) Approved in Europe for Psoriatic Arthritis and Severe Rheumatoid Arthritis
Abbott Laboratories announced that it has received US Food and Drug Administration (FDA) approval to market HumiraR (adalimumab)...
Wednesday Sep 28, 2005
New-Onset or Exacerbation of Psoriatic Skin Lesions in RA Patients on Tumor Necrosis Factor-Alpha Antagonists
Nine rheumatic arthritis (RA) patients treated with 3 different tumor necrosis factor-alpha (TNF-α) antagonist formulations developed new-onset or an exacerbation of psoriatic lesions, despite the efficacy of TNF-α antagonists in treating such psoriatic lesions in the past. These first-ever reported cases will likely spur further analysis of the unexpected phenomenon...Kary S, et al. Ann Rheum Dis. Online First. September 8, 2005.
Monday Aug 15, 2005
Abbott's Humira Approved in Europe for Psoriatic Arthritis and Early RA
Abbott Laboratories has received approval from the European Commission to market HumiraR...
Wednesday Jun 29, 2005
EMEA Recommends HumiraR as First Line for Moderate-to-Severe RA
Abbott Laboratories announced that the European Medicines Agency (EMEA) has recommended approval of HumiraR (adalimumab) for first-line treatment of moderate-to-severe early rheumatoid arthritis (RA).
Monday Jun 13, 2005
EULAR Report: Developments in the Treatment of Ankylosing Spondylitis Using TNF-α Inhibitors
Studies of low-dose regimens, the effects of discontinuation, and 52-week data from an initial study of adalimumab highlight the results presented at EULAR on the use of TNF-α inhibitors in the treatment of AS...Presented at Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Friday Jun 10, 2005
EULAR Report: TNF-α Inhibition and Mycobacterium TB Infection
Several epidemiological studies highlight the importance of prescreening for latent TB before initiation of TNF-α inhibitors... Presented at: Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Monday Jun 06, 2005
Trials Outline Effective Strategies for the Use of Existing Therapies in Ankylosing Spondylitis
Four new studies highlight ways to use non-steroidals, biologics, and methotrexate in ankylosing spondylitis. Marzo-Ortega H, et al. Ann Rheum Dis. 2005 May 26; [Epub ahead of print].
Tuesday May 17, 2005
Infliximab Approved for Treatment of Psoriatic Arthritis
Infliximab joins etanercept as an anti-TNF-α treatment option for patients with active psoriatic arthritis...FDA approves Remicade® for ninth indication: psoriatic arthritis [press release]. Malvern, Pa: Centocor, Inc; May 17, 2005.
Friday Apr 08, 2005
Thalidomide May Play a Role in Treatment of Refractory Radiculopathic Pain
Banned from use in the 1960s due to its teratogenic effects, thalidomide is being reexamined as a treatment for inflammatory and other types of disorders... Presented at the 24th Annual Scientific Meeting of the American Pain Society; March 30-April 2, 2005; Boston, Massachusetts
Wednesday Apr 06, 2005
Study Links TNF Inhibitors to Dermatologic Problems in Rheumatoid Arthritis Patients
Although a causative relationship has yet to be established, the new data put physicians on alert for a "less than major complication" Flendrie M, et al. Arthritis Res Ther. 2005;7:666-676.
Monday Mar 07, 2005
Latest Trial Results for Biologics in Psoriatic Arthritis
Highlighted results from the American Academy of Dermatology meeting confirm the efficacy of anti-TNF therapy in treating psoriatic arthritis...63rd Annual Meeting of the American Academy of Dermatology, February18-22, 2005; New Orleans, La.
Thursday Feb 03, 2005
Crohn's Disease Patients With Attenuated Response to Infliximab May Respond to Adalimumab
Mimicking the paradigm seen with TNF-blockade in rheumatoid arthritis, preliminary data suggest that switching infliximab nonresponders to adalimumab may improve the clinical response and reduce disease activity...Papadakis KA. Am J Gastroenterol. 2005;100:75-79.
Wednesday Oct 27, 2004
Anti-TNF Drugs Appear to Show Benefits in Most Ankylosing Spondylitis Patients and May Also Improve Psoriatic Arthritis
Recent study findings indicate that ankylosing spondylitis and psoriatic arthritis may respond well to infliximab, etanercept, and adalimumab... Rudwaleit M, Sieper J… Z Rheumatol. 2004;63:193-202.
Wednesday Oct 27, 2004
Anti-TNF Drugs Appear to Show Benefits in Most Ankylosing Spondylitis Patients – and May Also Improve Psoriatic Arthritis
Recent study findings indicate that ankylosing spondylitis and psoriatic arthritis may respond well to infliximab, etanercept, and adalimumab... Rudwaleit M, Sieper J… Z Rheumatol. 2004;63:193-202.
Friday Oct 22, 2004
Research Shows Benefits of TNF-α Blockers in Treating Ankylosing Spondylitis
Studies involving etanercept, infliximab, and adalimumab consistently show long-term benefits with regard to disease activity, function, and spinal mobility... Davis JC, et al. Presented at: Annual Meeting of the American College of Rheumatology; October 20, 2004; San Antonio, Tex.
Friday Oct 22, 2004
Research Shows Benefits of TNF-α Blockers in Treating Ankylosing Spondylitis
Studies involving etanercept, infliximab, and adalimumab consistently show long-term benefits with regard to disease activity, function, and spinal mobility... Davis JC, et al. Presented at: Annual Meeting of the American College of Rheumatology; October 20, 2004; San Antonio, Tex.
Thursday Oct 21, 2004
Treating Early and in Combination May Lessen Damage in Rheumatoid Arthritis
An emerging body of clinical evidence supports the concept that combination therapy with an antitumor necrosis factor-α agent and methotrexate brings symptomatic relief and reduces radiographic progression... Breedveld FC, et al. Presented at: Annual Meeting of the American College of Rheumatology; October 20, 2004; San Antonio, Tex.
Wednesday Oct 20, 2004
Adalimumab Markedly Reduces Psoriatic Arthritis Symptoms
Striking benefits are shown for psoriatic arthritis patients' skin and joint symptoms with adalimumab vs placebo... Mease PJ, et al. Presented at Annual Meeting of the American College of Rheumatology; October 19, 2004; San Antonio, Texas
Tuesday Oct 19, 2004
Emerging Data Underscore Long-Term Efficacy of Adalimumab in Combination With Methotrexate for RA
Several clinical trials presented at the ACR annual meeting demonstrated that the combination of adalimumab and MTX achieved clinical remission and inhibition of structural damage for up to 4 years... Schiff MH et al. Presented at: Annual Meeting of the American College of Rheumatology; October 19, 2004; San Antonio, Tex.
Wednesday Sep 15, 2004
Advances in anti-TNF Therapy for RA
Two studies give insight regarding the time after RA onset to introduce anti-TNF therapy, and which doses to use to get an optimal response. (Baumgartner SW, et al. J Rheumatol. 2004;31:1532-1537; Stern R, Wolfe F. J Rheumatol. 2004;31:1538-1545.)
Thursday Jun 10, 2004
Early Results of the ReAct Trial Confirm the Efficacy and Safety of Adalimumab (HUMIRA)
|
